市场调查报告书
商品编码
1401018
生物电医学全球市场规模、占有率、产业趋势分析报告:2023-2030 年按类型、最终用途、产品、应用、地区分類的展望与预测Global Bioelectric Medicine Market Size, Share & Industry Trends Analysis Report By Type, By End-use, By Product, By Application, By Regional Outlook and Forecast, 2023 - 2030 |
2030年,生物电医药市场规模预计将达317亿美元,预测期内市场成长率为6.1%。
根据 KBV Cardinal 矩阵中发布的分析,雅培实验室 (Abbott Laboratories) 和美敦力 (Medtronic PLC) 是市场推动者。 2021 年 11 月,美敦力 (Medtronic) PLC 与 Rune Labs 合作,该公司利用集中的大脑资料来推动神经和精神疾病精准药物的开发和交付。该合作伙伴关係旨在评估 BrainSense 技术的使用,这是第一个也是唯一一个能够长期捕获和记录脑波讯号的完整深部脑部刺激系统。 Boston Scientific Corporation、Nevro Corporation 和 electroCore, Inc. 等公司是该市场的主要创新者。
COVID-19 影响分析
疫情扰乱了全球供应链,影响了生物电设备和零件的生产和分销。封锁、旅行限制和劳动力挑战导致製造和供应延迟,影响了某些生物电技术的可得性。由于实验室暂时关闭且资源被重新分配到与 COVID-19 相关的研究,市场上的许多研发活动都被推迟。新生物电疗法的临床试验面临中断,影响了产品开发进度。因此,COVID-19的爆发对市场产生了负面影响。
市场成长要素
世界高龄化人口增加
老龄化过程与心血管疾病、神经神经退化性疾病(如阿兹海默症和帕金森氏症)、关节炎和其他与老龄化相关的疾病等慢性疾病的风险增加有关。生物电介入可以透过其调节生理过程的潜力提供有效管理和治疗这些疾病的新方法。生物电医学的目的不仅是治疗疾病,还旨在提高整体生活品质。生物电干预,包括神经调节和其他技术,可以改善这些方面并促进老年人生活品质的提高。预计这些因素将有助于市场扩张。
加大研发投入
对研究的投资可以帮助找到核准和商业化的监管途径。满足监管标准对于将生物电疗法推向市场至关重要,持续的投资将支持满足这些要求所需的研究和记录。产业领导者的资源投入将有助于扩大市场。随着新治疗方法的开发并被证明有效,它们可以覆盖更广泛的患者群体并提高市场渗透率。因此,这些因素预计将为市场提供良好的成长前景。
市场抑制因素
药品核准相关问题
寻求在国际上销售产品的生物电公司面临着适应多种法律规范的挑战。地区之间核准流程和要求的差异可能会增加整体监管时间表的复杂性和长度。监管机构可能面临调整现有框架以适应快速发展的生物电子医学技术的挑战。由于某些生物电疗法的新颖性和独特性,监管机构可能需要製定专门的指南。这些因素将阻碍市场的成长。
按类型分類的展望
按类型划分,市场可分为植入式电疗设备和非侵入性电疗设备。到2022年,非侵入性电疗设备领域将占据市场主要收益占有率。非侵入性电疗设备为侵入性手术提供了对患者友善的替代方案。患者通常喜欢非侵入性治疗,因为这种治疗可以减少疼痛、最小程度的不适并且无需手术干预。这种方法提高了患者的依从性并有助于营造积极的患者体验。技术进步对于开发先进的非侵入性电疗设备至关重要。经皮电刺激和非侵入性神经调节等创新技术正在扩大非侵入性干预的范围。因此,该领域很可能在未来几年内迅速扩张。
最终用途展望
根据最终用途,市场分为医院和其他。 2022 年,医院细分市场收益占有率最大。生物电干预正在广泛应用于各种医学专业,从神经病学和疼痛管理到心臟病学和復健。生物电疗法的多功能性使其能够治疗多种医疗状况,促使医院在各个部门探索和实施这些干预措施。因此,这些因素推动了医院领域的成长。
产品展望
产品分为植入式心臟整流去颤器/心臟节律器、人工电子耳耳蜗、脊髓刺激设备、深层脑部刺激器、经皮电神经刺激设备、荐/迷走神经刺激设备等。 2022 年,脊髓刺激设备领域在市场中获得了可观的收益占有率。脊髓刺激设备通常用作治疗慢性疼痛的选择,例如腰部手术失败综合症和复杂性局部疼痛症候群。这些疾病的盛行率不断上升,加上人口高龄化,可能会导致脊髓刺激设备的需求增加。因此,该领域很可能在未来几年内迅速扩张。
按用途分類的展望
依应用,市场分为心律不整、疼痛管理、感感音性听障、巴金森氏症、震颤/癫痫、忧郁症、抗治疗性忧郁症、尿液/大便失禁等。 2022年,震颤/癫痫细分市场在市场中占据很大的收益占有率。震颤和癫痫常伴随脑部异常电活动。神经调节疗法是生物电医学的关键组成部分,利用电刺激来调节神经活动。神经调节技术的进步可能为震颤和癫痫等疾病带来更有效的治疗方法。由于这些因素,该领域预计将迅速扩大。
区域展望
从区域来看,市场分为北美、欧洲、亚太地区和拉丁美洲地区。 2022 年,北美市场的收益占有率最高。北美特别是美国在医疗保健产业中发挥重要作用,拥有强大的医疗技术和创新产业。该地区处于生物电医学研究和开发的前沿。与学术机构、研究中心和产业的合作促进创新,并常常导致新生物电疗法和设备的开发。因此,预计该细分市场在未来几年将会成长。
The Global Bioelectric Medicine Market size is expected to reach $31.7 billion by 2030, rising at a market growth of 6.1% CAGR during the forecast period.
Deep brain stimulation (DBS) is a well-established technique involving implanted electrodes to deliver electrical impulses to specific brain regions, providing therapeutic benefits in conditions like Parkinson's disease. Therefore, Deep Brain Stimulators segment generated $1,022.1 million revenue in the market in 2022. Likewise, neuromodulation techniques, such as transcranial magnetic stimulation (TMS), and deep brain stimulation, are being explored for their potential in various neurological and psychiatric disorders. These techniques aim to modulate neural activity to restore normal functioning and alleviate symptoms. These aspects will lead to increased demand in the market.
The major strategies followed by the market participants are Partnerships, Collaborations & Agreements as the key developmental strategy to keep pace with the changing demands of end users. For instance, In August, 2021, electroCore, Inc. signed an agreement with Red One Medical Devices, LLC, a service-disabled veteran-owned small business. This agreement aimed to widen the availability of electroCore's gammaCore platform in the federal marketplace. Moreover, In May, 2020, Medtronic collaborated with UW following which the company has accelerated research into deep brain stimulation treatment for essential tremor, Parkinson's disease, and other neurological disorders.
Based on the Analysis presented in the KBV Cardinal matrix; Abbott Laboratories and Medtronic PLC are the forerunners in the Market. In November, 2021, Medtronic PLC partnered with Rune Labs, a company using aggregated brain data to empower the development and delivery of precision medicines for neurological and psychiatric diseases. This partnership aimed to assess the use of BrainSense technology, the first and only complete Deep Brain Stimulation system able to chronically capture and record brain signals. Companies such as Boston Scientific Corporation, Nevro Corporation and electroCore, Inc. are some of the key innovators in the Market.
COVID-19 Impact Analysis
The pandemic disrupted global supply chains, affecting the production and distribution of bioelectric devices and components. Lockdowns, travel restrictions, and workforce challenges led to delays in manufacturing and supply, impacting the availability of certain bioelectric technologies. Many research and development activities in the market experienced delays as laboratories were temporarily closed, and resources were redirected toward COVID-19-related research. Clinical trials for new bioelectric therapies faced interruptions, affecting timelines for product development. Therefore, the COVID-19 pandemic led to a negative impact on the market.
Market Growth Factors
Growing aging population globally
The aging process is associated with an increased risk of chronic diseases such as cardiovascular disorders, neurodegenerative conditions (like Alzheimer's and Parkinson's diseases), arthritis, and other age-related ailments. Bioelectric interventions, through their potential to modulate physiological processes, can offer novel approaches to manage and treat these conditions effectively. Bioelectric medicine aims not only to treat diseases but also to enhance the overall quality of life. Bioelectric interventions, including neuromodulation and other techniques, can improve these aspects and promote a better quality of life for elderly individuals. These factors will help in the expansion of the market.
Rising investments in research and development
Investment in research helps navigate regulatory pathways for approval and commercialization. Meeting regulatory standards is crucial for bringing bioelectric therapies to the market, and ongoing investment supports the necessary studies and documentation to meet these requirements. The commitment of resources from industry leaders contributes to expanding the market. As new therapies are developed and proven effective, they can reach a broader patient population, increasing market penetration. Therefore, these factors will pose lucrative growth prospects for the market.
Market Restraining Factors
Challenges related to regulatory approval
Bioelectric companies looking to market their products internationally face the challenge of navigating multiple regulatory frameworks. Differences in approval processes and requirements across regions can add complexity and length to the overall regulatory timeline. Regulatory agencies may face challenges in adapting existing frameworks to accommodate rapidly evolving technologies in bioelectric medicine. The novelty and uniqueness of some bioelectric therapies may require regulatory agencies to develop specialized guidelines. These elements will hamper the growth of the market.
Type Outlook
By type, the market is bifurcated into implantable electroceutical devices and non-invasive electroceutical devices. In 2022, the non-invasive electroceutical devices segment witnessed a substantial revenue share in the market. Non-invasive electroceutical devices provide a patient-friendly alternative to invasive procedures. Patients often prefer non-invasive treatments due to reduced pain, minimal discomfort, and the absence of surgical interventions. This approach enhances patient compliance and contributes to a positive patient experience. Technological advancements have been crucial in developing sophisticated, non-invasive electroceutical devices. Innovative technologies, such as transdermal electrical stimulation and non-invasive neuromodulation, have expanded the scope of non-invasive interventions. Therefore, the segment will expand rapidly in the upcoming years.
End-use Outlook
On the basis of end-use, the market is divided into hospitals and others. The hospitals segment recorded the maximum revenue share in the market in 2022. Bioelectric interventions are finding applications across various medical specialties, ranging from neurology and pain management to cardiology and rehabilitation. The versatility of bioelectric therapies makes them relevant for addressing diverse medical conditions, prompting hospitals to explore and implement these interventions within various departments. Thus, these factors will fuel the growth of the hospitals segment.
Product Outlook
Based on product, the market is segmented into implantable cardioverter defibrillators & cardiac pacemakers, cochlear implants, spinal cord stimulators, deep brain stimulators, transcutaneous electrical nerve stimulators, sacral & vagus nerve stimulators, and others. In 2022, the spinal cord stimulators segment garnered a significant revenue share in the market. Spinal cord stimulators are often used as a therapeutic option for managing chronic pain conditions, such as failed back surgery syndrome and complex regional pain syndrome. The rising prevalence of these conditions, coupled with a growing aging population, can contribute to an increased demand for spinal cord stimulators. Therefore, the segment will expand rapidly in the coming years.
Application Outlook
Based on application, the market is divided into arrhythmia, pain management, sensorineural hearing loss, Parkinson's disease, tremor & epilepsy, depression, treatment-resistant depression, urinary & fecal incontinence, and others. In 2022, the tremor and epilepsy segment witnessed a substantial revenue share in the market. Tremors and epilepsy often involve abnormal electrical activity in the brain. Neuromodulation therapies, a significant component of bioelectric medicine, involve the use of electrical stimulation to modulate neural activity. Advances in neuromodulation technologies may lead to more effective treatments for conditions such as tremors and epilepsy. These factors will lead to rapid expansion of the segment.
Regional Outlook
By region, the market is segmented into North America, Europe, Asia Pacific, and LAMEA. The North America segment procured the highest revenue share in the market in 2022. North America, particularly the United States, has been a significant player in the healthcare industry, with a robust industry for medical technologies and innovations. The region has been at the forefront of bioelectric medicine research and development. Academic institutions, research centers, and industry collaborations often drive innovation, leading to the development of novel bioelectric therapies and devices. Thus, the segment will witness increased growth in the coming years.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, Abbott Laboratories, Boston Scientific Corporation, Cochlear Ltd., LivaNova PLC, Koninklijke Philips N.V., Biotronik SE & Co. KG, Sonova Holding AG, Nevro Corporation, and electroCore, Inc.
Recent Strategies Deployed in Bioelectric Medicine Market
Mergers & Acquisition
May-2022: Medtronic plc acquired Intersect ENT, a medical technology company. This acquisition aimed to increase Medtronic's comprehensive ear, nose, and throat offering with innovative products used in sinus procedures to enhance post-operative outcomes and treat nasal polyps.
Nov-2021: Koninklijke Philips N.V. acquired Cardiology, a France-based medical technology company focused on transforming cardiac diagnostics using artificial intelligence (AI) and cloud technology. Through his acquisition, Koninklijke Philips N.V. would be able to strengthen its diagnostics offering and cardiac monitoring with electrocardiogram (ECG) analysis, creative software technology, and reporting services.
Feb-2021: Koninklijke Philips N.V. took over BioTelemetry, Inc., a leading U.S.-based provider of remote cardiac diagnostics and monitoring. Through this acquisition, Koninklijke Philips N.V. would be in a favourable position to enhance patient care across care environments for medical conditions and numerous diseases with the help of the combination of both the organization's portfolio and service platforms.
Jan-2020: Medtronic took over Stimgenics, a startup company that has developed a novel spinal cord stimulation waveform. This acquisition enabled the company to expand its business in the SCS Market.
Jun-2019: Boston Scientific acquired Vertiflex, a healthcare company. Through this acquisition, Vertiflex's spinal cord stimulation and radiofrequency ablation have been added to Boston Scientific's product portfolio.
Partnerships, Collaborations & Agreements
Nov-2021: Medtronic PLC partnered with Rune Labs, a company using aggregated brain data to empower the development and delivery of precision medicines for neurological and psychiatric diseases. This partnership aimed to assess the use of BrainSense technology, the first and only complete Deep Brain Stimulation system able to chronically capture and record brain signals.
Aug-2021: electroCore, Inc. signed an agreement with Red One Medical Devices, LLC, a service-disabled veteran-owned small business. This agreement aimed to widen the availability of electroCore's gammaCore platform in the federal marketplace.
May-2020: Medtronic collaborated with UW following which the company has accelerated research into deep brain stimulation treatment for essential tremor, Parkinson's disease, and other neurological disorders.
May-2019: Abbott came into partnership with the US National Institutes of Health (NIH). The partnership was aimed at developing unique insights and driving the application of neurostimulation therapies. The partnership would provide the latter company's neuroscience research initiative BRAIN access to Abbott's neuromodulation technologies.
Product Launches and Product Expansions
Dec-2022: electroCore, Inc. rolled out Truvaga, a new wellness product offering. The launched product aimed to provide a drug-free, simple, and convenient way to support in reducing stress with just 2-minute sessions, day and night; no apps, batteries, chargers, or phones are required.
Nov-2022: electroCore, Inc. introduced gammaCore Sapphire, the first and only FDA-cleared non-invasive device. The launch would be aimed at treating and preventing multiple types of headache pain via the vagus nerve.
Oct-2020: Abbott Laboratories introduced ICD (Implantable Cardioverter-Defibrillator), a medical device that monitors heart rhythms and delivers shocks to treat life-threatening arrhythmias, and CRT-D (Cardiac Resynchronization Therapy with Defibrillation), an ICD with an added feature to synchronize the contractions of the heart's ventricles, improving heart function in certain patients.
Jan-2020: Medtronic announced the CE mark for its Percept PC neurostimulator. This is a Deep Brain Stimulation (DBS) system with BrainSense technology. The system can sense and record brain signals while offering therapy to patients with neurologic disorders, such as Parkinson's disease.
Oct-2019: Medtronic launched Activa Programming, a new system. The system enables the patients in managing their deep brain stimulation (DBS) treatments at home using a dedicated and customized Samsung smartphone.
Jan-2019: Cochlear Ltd. launched Nucleus 7 Sound Processor, implantable hearing device for the people with single-sided deafness, conductive and mixed hearing loss.
Jan-2019: Boston launched WaveWriter Spinal Cord Stimulator (SCS) System in Europe for providing the treatment of chronic pain to people in Europe.
Jan-2019: Boston Scientific introduced the Vercise Primary Cell (PC) and Vercise Gevia Deep Brain Stimulation (DBS) Systems. The systems feature the Vercise Cartesia Directional Lead. The systems have the technology that enables the physicians in controlling the range, shape, position, and direction of electrical stimulation to treat the symptoms of Parkinson's disease (PD) through highly-personalized therapy.
Geographical Expansion
Sep-2019: Sonova opened a new training center in Germany. This expansion aimed to provide training program for hearing care professionals.
Mar-2019: Cochlear Ltd. expanded its reach to UK. This expansion aimed to provide the criteria for cochlear implant to professionals.
Approvals and Trials
Jul-2023: Abbott Laboratories got approval from the FDA for the AVEIR dual chamber (DR) leadless pacemaker system, an advanced medical device that offers dual-chamber pacing capabilities without the need for traditional leads or wires, improving patient comfort and reducing potential complications.
Oct-2022: Nevro Corporation got FDA approval for the Senza HFX iQ spinal cord stimulation (SCS) system, the first and only Artificial Intelligence-based SCS system. The approved product would address the variability in pain from patient to patient and support patients to optimize and maintain long-term pain relief and improved quality of life.
Jan-2021: Medtronic plc introduced the first enrollment in ADAPT-PD. This trial aimed to evaluate the safety and efficacy of adaptive deep brain stimulation (aDBS) in patients with Parkinson's Disease.
Jan-2020: Abbott Laboratories got approval from the US Food and Drug Administration (FDA) for its Infinity Deep Brain Stimulation (DBS) system. This system would be used in the treatment of Parkinson's disease. The system would enable targeting a specific area of the brain known as the internal globus pallidus (GPi) for improving the symptoms of Parkinson's disease not controlled by medication.
Nov-2019: Nevro Corporation received approval from the FDA for the Senza Omnia Spinal Cord Stimulation (SCS) System. The Omnia system has been designed to deliver Nevro's proprietary HF10 therapy in addition to all other available SCS frequencies.
Market Segments covered in the Report:
By Type
By End-use
By Product
By Application
By Geography
Companies Profiled
Unique Offerings from KBV Research